Cargando…
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target
The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associated protein, while its role in innate immune response upon viral infection remains still to b...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474792/ https://www.ncbi.nlm.nih.gov/pubmed/34565385 http://dx.doi.org/10.1186/s12967-021-03085-w |
_version_ | 1784575298451275776 |
---|---|
author | Capone, Emily Iacobelli, Stefano Sala, Gianluca |
author_facet | Capone, Emily Iacobelli, Stefano Sala, Gianluca |
author_sort | Capone, Emily |
collection | PubMed |
description | The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associated protein, while its role in innate immune response upon viral infection remains still to be clarified. Since its discovery dated in early 90 s, a large body of literature has been accumulating highlighting both a prognostic and functional role for LGALS3BP in cancer. Moreover, data from our group and other have strongly suggested that this protein is enriched in cancer-associated extracellular vesicles and may be considered a promising candidate for a targeted therapy in LGALS3BP positive cancers. Here, we extensively reviewed the literature relative to LGALS3BP role in cancer and its potential value as a therapeutic target. |
format | Online Article Text |
id | pubmed-8474792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84747922021-09-28 Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target Capone, Emily Iacobelli, Stefano Sala, Gianluca J Transl Med Review The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associated protein, while its role in innate immune response upon viral infection remains still to be clarified. Since its discovery dated in early 90 s, a large body of literature has been accumulating highlighting both a prognostic and functional role for LGALS3BP in cancer. Moreover, data from our group and other have strongly suggested that this protein is enriched in cancer-associated extracellular vesicles and may be considered a promising candidate for a targeted therapy in LGALS3BP positive cancers. Here, we extensively reviewed the literature relative to LGALS3BP role in cancer and its potential value as a therapeutic target. BioMed Central 2021-09-26 /pmc/articles/PMC8474792/ /pubmed/34565385 http://dx.doi.org/10.1186/s12967-021-03085-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Capone, Emily Iacobelli, Stefano Sala, Gianluca Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title | Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title_full | Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title_fullStr | Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title_full_unstemmed | Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title_short | Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
title_sort | role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474792/ https://www.ncbi.nlm.nih.gov/pubmed/34565385 http://dx.doi.org/10.1186/s12967-021-03085-w |
work_keys_str_mv | AT caponeemily roleofgalectin3bindingproteinincancerprogressionapotentialnoveltherapeutictarget AT iacobellistefano roleofgalectin3bindingproteinincancerprogressionapotentialnoveltherapeutictarget AT salagianluca roleofgalectin3bindingproteinincancerprogressionapotentialnoveltherapeutictarget |